FreshPatents.com Logo
Enter keywords:  

Track companies' patents here: Public Companies RSS Feeds | RSS Feed Home Page
Popular terms

[SEARCH]

Follow us on Twitter
twitter icon@FreshPatents

Web & Computing
Cloud Computing
Ecommerce
Search patents
Smartphone patents
Social Media patents
Video patents
Website patents
Web Server
Android patents
Copyright patents
Database patents
Programming patents
Wearable Computing
Webcam patents

Web Companies
Apple patents
Google patents
Adobe patents
Ebay patents
Oracle patents
Yahoo patents

[SEARCH]

Cholesterol patents



      
           
This page is updated frequently with new Cholesterol-related patent applications. Subscribe to the Cholesterol RSS feed to automatically get the update: related Cholesterol RSS feeds. RSS updates for this page: Cholesterol RSS RSS


Date/App# patent app List of recent Cholesterol-related patents
04/23/15
20150111948
 Rna-interference-inducing nucleic acid molecule able to penetrate into cells, and use therefor patent thumbnailnew patent Rna-interference-inducing nucleic acid molecule able to penetrate into cells, and use therefor
The present invention relates to a novel, rnai-inducing nucleic acid molecule having cell penetrating ability and the use thereof, and more particularly, to a novel, rnai-inducing double-stranded nucleic acid molecule, which has a replacement of the phosphate backbone of at least one nucleotide with phosphorothioate or phosphorodithioate, and has a lipophilic compound conjugated thereto, and thus has high target gene-silencing efficiency while having the ability to penetrate cells without needing a separate intracellular delivery vehicle, and to a method of silencing a target gene using the nucleic acid molecule. The nucleic acid structure according to the present invention has both cholesterol modification and phosphorothioate modification introduced therein, and thus has high gene silencing efficiency while having the ability to penetrate cells without needing a separate intracellular delivery vehicle.
Bmt, Inc.
04/23/15
20150111866
 Cyclic amine substituted heterocyclic cetp inhibitors patent thumbnailnew patent Cyclic amine substituted heterocyclic cetp inhibitors
Compounds having the structure of formula i, including pharmaceutically acceptable salts of the compounds, are cetp inhibitors and may be useful for raising hdl-cholesterol and reducing ldl-cholesterol in human patients and for treating or preventing atherosclerosis.. .
Merck Sharp & Dohme Corp.
04/23/15
20150110859
 Mrna therapy for argininosuccinate synthetase deficiency patent thumbnailnew patent Mrna therapy for argininosuccinate synthetase deficiency
The present invention provides, among other things, methods of treating argininosuccinate synthetase deficiency (asd), including administering to a subject in need of treatment a composition comprising an mrna encoding argininosuccinate synthetase (ass1) at an effective dose and an administration interval such that at least one symptom or feature of asd is reduced in intensity, severity, or frequency or has delayed in onset. In some embodiments, the mrna is encapsulated in a liposome comprising one or more cationic lipids, one or more non-cationic lipids, one or more cholesterol-based lipids and one or more peg-modified lipids.
Shire Human Genetic Therapies, Inc.
04/23/15
20150110858
 Mrna therapy for phenylketonuria patent thumbnailnew patent Mrna therapy for phenylketonuria
The present invention provides, among other things, methods of treating phenylketonuria (pku), including administering to a subject in need of treatment a composition comprising an mrna encoding phenylalanine hydroxylase (pah) at an effective dose and an administration interval such that at least one symptom or feature of pku is reduced in intensity, severity, or frequency or has delayed in onset. In some embodiments, the mrna is encapsulated in a liposome comprising one or more cationic lipids, one or more non-cationic lipids, one or more cholesterol-based lipids and one or more peg-modified lipids.
Shire Human Genetic Therapies, Inc.
04/16/15
20150104847
 Method for stabilizing cholesterol oxidase patent thumbnailMethod for stabilizing cholesterol oxidase
The present invention provides a method for stabilizing a cholesterol oxidase, a method for preserving a cholesterol oxidase, and a stabilized composition of cholesterol oxidase. A method for stabilizing a cholesterol oxidase and a method for preserving a cholesterol oxidase which comprises allowing the cholesterol oxidase to coexist with an α-keto acid in an aqueous medium, and, a stabilized composition of cholesterol oxidase which comprises the cholesterol oxidase being allowed to coexist with an α-keto acid in an aqueous medium.
Kyowa Medex Co., Ltd.
04/16/15
20150104817
 Hydroxycholesterol immunoassay patent thumbnailHydroxycholesterol immunoassay
Provided is a derivative of 22-hydroxycholesterol, 24s-hydroxycholesterol, 25-hydroxycholesterol, 26-hydroxycholesterol or 27-hydroxycholesterol. Also provided is a protein conjugated to the above derivative.
Enzo Life Sciences, Inc. C/o Enzo Biochem, Inc.
04/16/15
20150104532
 Composition to enhance hdl cholesterol and to decrease intima-media thickening in animals and humans and a  its preparation patent thumbnailComposition to enhance hdl cholesterol and to decrease intima-media thickening in animals and humans and a its preparation
A method of producing a product to correct hypercholesterolemia including pulping fruits of emblica officinalis with demineralized water to create a slurry. The slurry is treated with pectinase.
Arjuna Natural Extracts, Ltd.
04/09/15
20150099787
 Non-flushing niacin analogues, and methods of use thereof patent thumbnailNon-flushing niacin analogues, and methods of use thereof
One aspect of the present invention relates to substituted pyridines and pharmaceutially acceptable salts thereof that are active against a range of mammalian maladies. Another aspect of the invention relates to a pharmaceutical composition, comprising a compound of the present invention or a pharmaceutically acceptable salt thereof; and a pharmaceutically acceptable excipient.
Trustees Of Tufts College
04/09/15
20150099021
 Medicinal composition of extract of seed of emblica officinalis and  preparing the same patent thumbnailMedicinal composition of extract of seed of emblica officinalis and preparing the same
A composition having an extract of seed of emblica officinalis. Methods of preparing extract of seed of emblica officinalis.
04/02/15
20150093781
 Microorganism for expressing a human membrane protein patent thumbnailMicroorganism for expressing a human membrane protein
The invention relates to an isolated, genetically modified, living non-mammal organism, having increased hmg-coa-reductase activity compared to the wild type, and having reduced c24-methyltransferase and/or delta22-desaturase activity compared to the wild type. The invention is characterized in that the organism has increased dehydrocholesterol-delta70-reductase activity compared to the wild type.
Organobalance Gmbh
04/02/15
20150093459

Bioactive complex compositions and methods of use thereof


A bioactive complex composition having enhanced oxidative stability, emulsion stability, mineral rich transparent beverages and a wide range of functional health benefits. The composition may include as a base composition individual ingredients or a synergistic blend of mineral salts, omega-3 rich oils, phospholipids, chitosan, and alpha-casein, beta-casein, kappa-casein or protein fragments, glycopeptides, phosphopeptides.
Texas A&m University System
03/26/15
20150087819

Antigen binding proteins to proprotein convertase subtilisin kexin type 9 (pcsk9)


Antigen binding proteins that interact with proprotein convertase subtilisin kexin type 9 (pcsk9) are described. Methods of treating hypercholesterolemia and other disorders by administering a pharmaceutically effective amount of an antigen binding protein to pcsk9 are described.
Amgen Inc.
03/26/15
20150087649

Treating disorders associated with aberrant adrenocortical cell behavior


Methods and agents are provided for treatment of disorders associated with aberrant adrenocortical cell behavior, including (but not limited to) treatment of adrenocortical carcinoma (acc) and/or cushing's syndrome. Such methods involve administration of an agent which exhibits an ic50 value against huacat1 of less than 10 μm, and one or more further characteristics including effects on adrenocortical cells, disruption of cholesterol homeostasis, reduction in steroid biosynthesis, reduction of mitochondrial function, and/or preferential binding to by low-density lipoprotein (ldl)..
Atterocor, Inc.
03/19/15
20150080477

Methods and compositions for treating arteriosclerotic vascular diseases


The present invention provides methods and compositions for treating arteriosclerotic vascular diseases by cyclohexenone compounds. In some embodiments, the compound in the methods inhibits pdgf-stimulated smooth muscle cell proliferation or migration.
Golden Biotechnology Corporation
03/19/15
20150080471

Methods for reducing triglyceride, total cholesterol and low density lipoprotein blood levels


Or a metabolite thereof, or an ester of the compound of formula (i) or the metabolite thereof, or a pharmaceutically acceptable salt of each thereof, wherein m, n, x1 and x2 are as defined herein, is useful for reducing blood levels of one or more of triglycerides (tg), total cholesterol (tc) and low density lipoprotein (ldl) in human subjects.. .
03/19/15
20150080345

Compositions and methods for the treatment of metabolic syndrome


The invention relates to the compounds of formula i and formula ii or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula i or formula ii, and methods for treating or preventing or modulating metabolic syndrome may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection.
03/19/15
20150079616

Method for quantifying subfraction of cholesterol (-c) in high-density lipoprotein (hdl)


Provided is a method for separately or simultaneously quantifying whole hdl-c and cholesterol in hdl subfractions: apoe-containing hdl-c and apoe-deficient hdl-c. A method for enzymatically and separately quantifying cholesterol in the apoe-deficient hdl comprising: adding a surfactant composed of a polyoxyethylene benzyl phenyl ether derivative to a test sample in a final concentration of 0.05 to 0.10%, reacting the test sample with cholesterol esterase and cholesterol oxidase, and quantifying hydrogen peroxide generated.
National University Corporation Hokkaido University
03/19/15
20150079226

Vegetable oil composition containing palm mid-fraction fat and reducing plasma cholesterol


A method and composition for reducing the cholesterolemic effect in mammals of ingesting a blended nutritional fat composition containing a palm mid-fraction (pmf) hardstock fat combined with an unsaturated vegetable oil. The composition is solid or semi-solid at 20° c.
Brandeis University
03/19/15
20150079225

Nutritional composition


A nutritional composition having a total energy content of 67 kcal/100 ml or lower and including: a protein content which is 1.25 g/100 ml or lower, an energy content from protein of 7.2-8.4% of the total energy content of the nutritional composition, an energy content from fat which is at least 49% or more of the total energy content of the nutritional composition, a medium chain fatty acid content comprising 8 to 10 carbons which is less than 3 wt % of total amount of fatty acids, a sialic acid content of 10-25 mg/100 ml, a cholesterol content of 5-10 mg/100 ml, and a sphingomyelin content of 9-15 mg/100 ml is disclosed.. .
Hero Ag
03/19/15
20150079189

Nanoparticulate compositions for targeted delivery of acid labile, lipophilic prodrugs of cancer chemotherapeutics and their preparation


In one embodiment, the present application discloses synthetic ldl nanoparticles comprising mixtures of components selected from the group consisting of phospholipids, triglycerides, cholesterol ester and free cholesterol; optionally further comprising an agent selected from the group consisting of natural antioxidants, ubiquinol and vitamin e, and methods for preparing the synthetic nanoparticles. The disclosed synthetic ldl nanoparticles are capable of selectively delivering lipophilic drugs and prodrugs to cellular targets expressing ldl receptors after intra venous injection..
Arbor Therapeutics, Llc
03/19/15
20150079161

Method for selectively inhibiting acat1 in the treatment of neurodegenerative diseases


The present invention features methods for stimulating clearance of misfolded or aggregated proteins or peptides in microglia or neurons, and treating neurodegenerative diseases associated with such pathology in brain by selectively inhibiting the expression or activity of acyl-coa:cholesterol acyltransferase 1, but not acyl-coa:cholesterol acyltransferase 2.. .
Trustees Of Dartmouth College
03/12/15
20150072962

Novel cholesterol metabolite, 5-cholesten, 3beta-25-diol, disulfate (25hcds) for therapy of metabolic disorders, hyperlipidemia, diabetes, fatty livers diseases and atherosclerosis


5-cholesten, 3β, 25-diol, disulfate (25hcds) has been found to be an authentic pparγ agonist and lxr antagonist, and is used for the therapy of lipid disorders and inflammatory diseases, including without limitation fatty liver, inflammatory bowel, and atherosclerotic diseases.. .
Virgini Commonwealth University
03/12/15
20150072955

Compounds for the prevention and treatment of cardiovascular diseases


The present disclosure relates to compounds, which are useful for regulating the expression of apolipoprotein a-i (apoa-i), and their use for treatment and prevention of cardiovascular disease and related disease states, including cholesterol- or lipid-related disorders, such as, for example, atherosclerosis.. .
Resverlogix Corp.
03/12/15
20150071857

Steroid hormone and cholesterol pathways as one unified homeostatic system


A unified homeostatic system of cholesterol and steroid hormone pathways is described, in which the uses or modulations of function of the homeostatic system of cholesterol and steroid hormone pathways are linked by lipoproteins, and are used or modulated to achieve a therapeutic benefit, to diagnose a disease or medical condition in humans, or to develop suitable active agents or combinations of active agents. Pharmaceutical compositions, methods of treatment, methods of drug development, and assay methods that rely on the new understanding of the homeostatic system are described..
Ligand Pharmaceuticals, Inc.
03/05/15
20150064786

In vitro model for neuronal death


This invention demonstrates the formation of a novel polarized membrane lipid raft signaling module in neurons, in response to several diverse neurotoxic stimuli. This polarization occurs well before neurons commit to die, and is an early mechanism in death signaling.
03/05/15
20150064271

Lactococcus lactis strains for the production of bioactive peptides having anti-hypertensive and cholesterol-lowering effects


New lactococcus lactis strains, nrrl b-50571 and nrrl b-50572, and a bacterial preparation containing the same, have the ability to produce bioactive peptides that reduce blood pressure, lower ldl-cholesterol (bad cholesterol) and present antioxidant properties for better cardiovascular health. These biologically active peptides may be produced within the food for the production of a food product, such as a functional food, or they may be produced from protein sources and subsequently added to a food as part of the formulation or as part of a food supplement or a pharmaceutical preparation..
Centro De Investigación En Alimentacion Y Desarrollo, A.c. (ciad)
03/05/15
20150064255

Nanostructures for treating cancers and other conditions


Nanostructures, compositions and methods for treating cancers and other conditions are provided. In some cases, the nanostructures and/or compositions may be used to treat cancers or other diseases or conditions at least in part by controlling cholesterol metabolism in cells.
Northwestern University
03/05/15
20150064115

Neurophilic nanoparticles


Novel liposomal nanoparticle that has been engineered to be particularly useful for the delivery of compounds to cells found in the peripheral nervous system, and to endothelial cells that form the blood brain barrier. These nanoparticles are intended to be useful for the delivery of compounds suitable for therapeutic purposes and imaging contrast agents that may not otherwise gain access to neuronal axons, or glial cells regions of the brain.
University Of Florida Research Foundation, Inc.
02/26/15
20150057373

Diether based biodegradable cationic lipids for sirna delivery


Disclosed herein are novel cationic lipids that can be used in combination with other lipid components such as cholesterol and peg-lipids to form lipid nanoparticles with oligonucleotides. The cationic lipids can demonstrate enhanced efficacy along with lower liver toxicity as a result of lower lipid levels in the liver.
Sirna Therapeutics, Inc
02/26/15
20150056269

Liposome comprising at least one cholesterol derivative


More particularly the invention relates to liposomes comprising at least one cholesterol derivative and compositions comprising said liposomes.. .
02/19/15
20150052635

Gene encoding enzyme that reduces position 24 of steroid skeleton and plant in which expression level of the gene is lowered


This invention provides a plant belonging to the family solanaceae that does not produce cholesterols, including glycoalkaloids. This invention concerns a protein having activity of an enzyme that reduces position 24 of the steroid skeleton of a plant belonging to the family solanaceae, a novel plant in which a gene encoding such protein is suppressed, and a method for producing and testing such plant..
Kirin Holdings Kabushiki Kaisha
02/19/15
20150051159

Lactococcus lactis strains


New lactococcus lactis strains, nrrl b-50571 and nrrl b-50572, and a bacterial preparation containing the same, have the ability to produce bioactive peptides that reduce blood pressure, lower ldl-cholesterol (bad cholesterol) and present antioxidant properties for better cardiovascular health. These biologically active peptides may be produced within the food for the production of a food product, such as a functional food, or they may be produced from protein sources and subsequently added to a food as part of the formulation or as part of a food supplement or a pharmaceutical preparation..
Centro De Investigación En Alimentacion Y Desarrollo, A.c. (ciad)
02/19/15
20150051144

Compounds for the treatment of dyslipidemia and other diseases


The present invention relates to compounds of the general formula (i), their tautomeric forms, their stereoisomers, their pharmaceutically acceptable salts, pharmaceutical compositions containing them, methods for their preparation, use of these compounds in medicine and the intermediates involved in their preparation. The present invention is directed towards compounds which can be used to treat diseases such as hyperlipidemia and also have a beneficial effect on cholesterol..
Cadila Healthcare Limited
02/19/15
20150050293

Flagellum and anti-flagellum antibody levels in samples as a diagnostic biomarker and therapeutic target for metabolic syndrome


High levels of bacterial flagella in a sample such as a gastrointestinal sample and/or low levels of anti-flagella antibodies serve as an indication for metabolic syndrome (such as insulin resistance, hypertension, elevated cholesterol, increased risk for blood clotting, and obesity) with highest levels of adiposity. An intervention that reduces the level and/or activity of flagella in the gastrointestinal tract can mitigate the severity of metabolic syndrome or in protecting against the development of metabolic syndrome..
Cornell University
02/19/15
20150050255

Lactococcus lactis strains


New lactococcus lactis strains, nrrl b-50571 and nrrl b-50572, and a bacterial preparation containing the same, have the ability to produce bioactive peptides that reduce blood pressure, lower ldl-cholesterol (bad cholesterol) and present antioxidant properties for better cardiovascular health. These biologically active peptides may be produced within the food for the production of a food product, such as a functional food, or they may be produced from protein sources and subsequently added to a food as part of the formulation or as part of a food supplement or a pharmaceutical preparation..
Centro De Investigación En Alimentacion Y Desarrollo, A.c. (ciad)
02/12/15
20150045563

Novel forms of [r-(r*,r*)]-2-(4-fluorophenyl)-beta, gamma-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrrole-1-heptanoic acid calcium salt (2:1)


Novel forms of [r—(r*,r*)]-2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrrole-1-heptanoic acid hemi calcium salt designated form xx, form xxi, form xxii, form xxiii, form xxiv, form xxv, form xxvi, form xxvii, form xxviii, form xxix, and form xxx, characterized by their x-ray powder diffraction, solid-state nmr, and/or raman spectroscopy are described, as well as methods for the preparation and pharmaceutical composition of the same, which are useful as agents for treating hyperlipidemia, hypercholesterolemia, osteoporosis, benign prostatic hyperplasia (bph) and alzheimer's disease.. .
Warner-lambert Company Llc
02/12/15
20150044774

Method for quantifying cholesterol in high density lipoprotein 3


Disclosed is the provision of a method for quantifying hdl3 in a test sample without requiring a laborious operation. The method for quantifying cholesterol in high-density lipoprotein 3 comprises allowing a surfactant(s) which specifically react(s) with a high-density lipoprotein 3 to react with a test sample and quantifying cholesterol, and the surfactant(s) is(are) at least one selected from the group consisting of polyoxyethylene polycyclic phenyl ether and polyoxyethylene styrenated phenyl ether..
Denka Seiken Co., Ltd
02/05/15
20150038566

Regulation of cholesterol homeostasis


The invention provides novel compounds of formulas (i)-(iv), as described herein. Also provided are compositions of these compounds, method of making the compounds, and methods of using the compounds.
University Of Notre Dame Du Lac
02/05/15
20150038550

Targeting micrornas for metabolic disorders


Provided herein are methods and compositions for the treatment of metabolic disorders. Also provided herein are methods and compositions for the reduction of blood glucose level, the reduction of gluceoneogenesis, the improvement of insulin resistance and the reduction of plasma cholesterol level.
Eth Zurich
01/29/15
20150031870

Antigen binding proteins to proprotein convertase subtilisin kexin type 9 (pcsk9)


Antigen binding proteins that interact with proprotein convertase subtilisin kexin type 9 (pcsk9) are described. Methods of treating hypercholesterolemia and other disorders by administering a pharmaceutically effective amount of an antigen binding protein to pcsk9 are described.
Amgen Inc.
01/29/15
20150031769

Methods for reducing triglyceride, total cholesterol and low density lipoprotein blood levels


Or a metabolite thereof, or an ester of the compound of formula (i) or the metabolite thereof, or a pharmaceutically acceptable salt of each thereof, wherein m, n, x1 and x2 are as defined herein, is useful for reducing blood levels of one or more of triglycerides (tg), total cholesterol (tc) and low density lipoprotein (ldl) in human subjects.. .
01/29/15
20150031058

Driving patient compliance with therapy


Methods of the invention involve determining a patient's compliance with a cholesterol lowering therapy. In certain aspects, the invention provides methods that involve conducting a first assay to determine a cholesterol biomarker level in a first sample from a patient prior to the patient undergoing a cholesterol lowering therapy.
Boston Heart Diagnostics Corporation
01/29/15
20150030581

Lpl variant therapeutics


The invention provides for the use of a therapeutic derived from a truncated lipoprotein lipase protein (lpl s447x), including nucleic acids encoding such proteins, for the treatment of conditions including lpl responsive conditions, such as cardiovascular disease, hypertension, lpl deficiency, high triglyceride levels, low hdl-cholesterol levels or atherosclerosis.. .
01/22/15
20150024077

Composition for treating skin barrier and reducing acne


A composition for applying to skin suffering from acne to treat the acne, the composition comprising an extract of malva neglecta. The malva neglecta increases ceramide production at the area of skin affected by acne to treat and/or improve the acne.
Johnson & Johnson Consumer Companies Inc.
01/22/15
20150024074

Methods for treating skin barrier and reducing acne


A method of treating acne by applying to the skin an extract of malva neglecta topically to the area of skin affected by acne to increase ceramide production at the area of skin affected by acne to treat and/or improve the acne. Additionally, cholesterol may also be applied to the area of skin along with the malva neglecta to treat and/or improve the acne..
Johnson & Johnson Consumer Companies Inc.
01/22/15
20150024009

Genetically modified organism for the production of lipids


The invention provides an isolated genetically modified non-mammalian organism, wherein the activity of acyl-coa:sterol acyltransferase/sterol o-acyltransferase (ec 2.3.1.26) and/or diacylglycerol acyltransferase/diacylglycerol o-acyltranferase (ec 2.3.1.20) and/or lecithin cholesterol acyl transferase/phospholipid: diacylglycerol acyltransferase (ec 2.3.1.158) and/or acyl coa-wax alcohol acyltransferase (ec 2.3.1.75) is reduced or abolished in comparison with a corresponding wildtype organism, methods of use of such an organism, shuttle vehicles for making such an organism and methods for producing such an organism.. .
Organobalance Gmbh
01/15/15
20150019269

System for rule-based insurance underwriting suitable for use by an automated system


A system for at least a partial underwriting of insurance policies is described. Various rules are created, along with a degree of satisfaction for each rule.
Genworth Holdings, Inc.
01/15/15
20150018384

Treatment for high cholesterol


The present invention provides a method for treatment of high cholesterol by reducing low density lipoprotein cholesterol (ldl-c) and/or very low density opoproiein cholesterol (vldl-c) in subjects in need thereof by administering a compound that inhibits hif hydroxylase activity. The method is useful, for reducing ldl cholesterol levels and total cholesterol levels even in subjects already undergoing treatment with other cholesterol-lowering medications, for example statins, fibrates, nicotinic acids and bile acid-binding resins, and in patients having chronic kidney disease or end stage renal disease, inter alia..
Fibrogen, Inc.
01/15/15
20150017244

Dry powder formulation of azole derivative for inhalation


A spray dried-powder composition for inhalation comprising particles (x) containing (a) between 5 and 50% by weight of at least one azole derivative in amorphous state but not in crystalline structure and (b) at least one matricial agent to the composition selected from a group consisting of polyol such as sorbitol, mannitol and xylitol; a monosaccharides such as glucose and arabinose; disaccharide such as lactose, maltose, saccharose and dextrose; cholesterol, and any mixture thereof, wherein the composition provides a dissolution rate of said azole derivative of at least, 5% within 10 minutes, 10% within 20 minutes and 40% within 60 minutes when tested in the dissolution apparatus type 2 of the united states pharmacopoeia at 50 rotation per minute, 37° c. In 900 milliliters of an aqueous dissolution medium adjusted at ph 1.2 and containing 0.3% of sodium laurylsulfate..
Galephar Pharmaceutical Research, Inc.
01/15/15
20150017183

Single domain antibodies as inhibitors of pcsk9


Antibodies (e.g., sdabs) binding to pcsk9 are described. Nucleic acids encoding such abs, host cells expressing such abs and pharmaceutical composition comprising same are described.
National Research Council Canada
01/08/15
20150011595

Inhibitors of cholesterol ester transfer protein


The invention relates to novel oxazolidinones their derivatives, pharmaceutically acceptable salts, solvates, and hydrates thereof. This invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating diseases and conditions that are beneficially treated by administering cholesterol ester transfer protein inhibitors..
Concert Pharmaceuticals, Inc.
01/08/15
20150011520

Pharmaceutical compositions to reduce complications of ocular steroid


The present invention relates to pharmaceutical compositions comprising a combination of a lipid cake mixture comprising one or more phospholipids, with or without cholesterol, and a steroid solution comprising an ocular steroid, derivative thereof a pharmaceutically acceptable salt thereof or a prodrug thereof, wherein the total amount of the phospholipid in the said composition is about 0.1 umol to less than about 2.5 umol per 50 ul of pharmaceutical composition and the side effects of the ocular steroid are reduced. The pharmaceutical composition is preferably administered by ocular route to treat ophthalmic diseases..
Tlc Biopharmaceuticals, Inc.
01/08/15
20150010615

Supercritical guggul extracts and uses thereof


The subject invention pertains to supercritical carbon dioxide extracts of commiphora mukul resin (guggul), which can be modified or not modified by some ethanol addition; methods for their production; and methods of use, such as inhibiting hmg-coa reductase, inhibiting transformation of pre-adipocytes to adipocytes, inhibiting triglyceride storage, promoting insulin sensitivity in adipocytes, treatment of disorders (for example, hypercholesterolemia, hyperlipidemia, hyperglycemia, obesity, metabolic syndrome, cardiovascular disease, atherosclerotic heart disease, autoimmune disorder, insulin resistance, leptin resistance, arthritis, cell proliferation disorder, such as cancer and atherosclerosis; damaged skin, sores, cuts, rashes, bruises, dryness, burns, sunburn, radiation burn, and infection), and regulating or suppressing appetite.. .
Flavex Naturextrakte Gmbh
01/01/15
20150005372

Compositions and methods of altering cholesterol levels


The present invention relates to compositions, methods and kits using polynucleotides, primary transcripts and mmrna molecules.. .
Moderna Therapeutics, Inc.
01/01/15
20150004268

Fat-based food products


The invention is in particular concerned with a food product comprising one or more fats or oils and a carotenoid compound. The products of the invention may be used in reducing elevated total cholesterol, triglycerides and inflammatory damage, as well as improving tissue microcirculation and tissue oxygenation..
Ip Science Limited
01/01/15
20150004218

Compositions and methods for immune tolerance induction


Methods and compositions to reduce immunogenicity of proteins are disclosed. Compositions comprising therapeutic proteins (such as factor viii or any other protein or peptide) complexed with liposomes comprising ps and pc (ps liposomes), or comprising ps, pi and pc and, optionally, cholesterol (ps/pi liposomes) may be used..
The Research Foundation For The State University Of New York
01/01/15
20150004174

Methods for treating homozygous familial hypercholesterolemia


The present invention relates to methods for treating homozygous familial hypercholesterolemia using antibodies against proprotein convertase subtilisin/kexin type 9 (pcsk9).. .
Amgen Inc.
01/01/15
20150004140

Compositions and methods for making alpha-(1,2)-branched alpha-(1,6) oligodextrans


Compositions for improving the health of a subject comprise alpha-(1,2)-branched alpha-(1,6) oligodextrans, preferably with an average molecular weight between about 10 kda and 70 kda, between about 10% and 50% alpha-(1,2)-osidic side chains, and having at least partial indigestibility in the subject. Methods for improving the health of a subject comprise administering the composition to a subject in an amount effective to improve gut health, or to prevent or treat a gastrointestinal disorder, a cholesterol-related disorder, diabetes, or obesity.
Tate & Lyle Ingredients France Sas


Popular terms: [SEARCH]



Follow us on Twitter
twitter icon@FreshPatents

###

This listing is a sample listing of patent applications related to Cholesterol for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Cholesterol with additional patents listed. Browse our RSS directory or Search for other possible listings.
     SHARE
  
         











0.3737

3694

1 - 1 - 74